G-CSF for imatinib-induced neutropenia [2]

Leukemia

Volumn 17, Issue 4, 2003, Pages 805-807

  Heim, D ^a   Ebnother M ^a   Meyer Monard, S ^a   Tsakiris, D ^a   Linn, M ^b   Tichelli, A ^a   Gratwohl, A ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Novartis Pharma Schweiz AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; BONE MARROW TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; LETTER; MALE; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0242668791     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402869     Document Type: Letter

References (7)

1. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99(10): 3530-3539.
2. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99(6): 1928-1937.
3. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346(9): 645-652.
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038-1042.
5. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood 1995; 85(12): 3636-3645.
6. Mauro MJ, O'Dwyer ME, Kurilik G, Blasdel C, Farnsworth M, Fong D et al. Risk factors for myelosuppression in chronic phase CML patients treated with Imatinib Mesylate (STI571). Blood 2001; 98(11): 139a.
7. Marin D, Bua M, Marktel S, Chase A, Udom C, Armstrong L et al. The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of Interferon-alfa defines four different prognostic groups. Blood 2001; 98(11): 846a.